RESUMO
This study aimed to investigate the myocardial protective effect of liquid sodium phosphocreatine cardiac arrest in extracorporeal circulation surgery treating infants with atrial septal defects.Eighty-four infants with atrial septal defects who required extracorporeal circulation surgery treatment at our hospital from January 2016 to June 2018 were divided into an observation group and a control group through a digitally randomized method, with 42 cases in each group. The control group adopted the conventional modified St Thomas II high potassium cold liquid crystal cardiac arrest, while the observation group adopted the liquid sodium phosphocreatine cardiac arrest.The myocardial enzyme indexes of the 2 groups 3, 6, 12, and 24âhours postoperatively were higher than before establishing the cardiopulmonary bypass and the enzyme indexes of the control group at the same time were higher than that of the observation group; adenosine triphosphate, adenosine diphosphate, and other energy levels and the postoperative recovery rate energy levels of the observation group were higher than those in the control group, the difference was statistically significant (Pâ<â.05).Liquid sodium phosphocreatine cardiac arrest used in extracorporeal circulation surgery treating infants with atrial septal defects can reduce myocardial ischemia-reperfusion injury, maintain energy supply during ischemia, strengthen the St Thomas II effect, and aid postoperative cardiac function recovery of high potassium cold liquid crystal cardiac arrest used in infants with atrial septal defects and treated with extracorporeal circulation surgery.
Assuntos
Ponte Cardiopulmonar/métodos , Cardiotônicos/farmacologia , Parada Cardíaca Induzida/métodos , Comunicação Interatrial/cirurgia , Fosfocreatina/farmacologia , Difosfato de Adenosina/metabolismo , Trifosfato de Adenosina/metabolismo , Cardiotônicos/administração & dosagem , Estudos de Casos e Controles , Pré-Escolar , Circulação Extracorpórea/métodos , Feminino , Parada Cardíaca/induzido quimicamente , Comunicação Interatrial/diagnóstico , Comunicação Interatrial/tratamento farmacológico , Humanos , Lactente , Masculino , Traumatismo por Reperfusão Miocárdica/prevenção & controle , Miocárdio/química , Miocárdio/enzimologia , Preservação de Órgãos/métodos , Fosfocreatina/administração & dosagem , Período Pós-Operatório , Cloreto de Potássio/administração & dosagem , Cloreto de Potássio/farmacologia , Substâncias Protetoras/administração & dosagem , Recuperação de Função Fisiológica/efeitos dos fármacosRESUMO
OBJECTIVE: This study aimed to compare the efficacy and safety of ulinastatin combined with creatine phosphate sodium and ribavirin combined with creatine phosphate sodium in the treatment of pediatric viral myocarditis. PATIENTS AND METHODS: 155 children with viral myocarditis in the Xuzhou Children's Hospital, were retrospectively analyzed. 80 of them received ulinastatin combined with creatine phosphate sodium, and were regarded as observation group; other 75 patients received ribavirin combined with creatine phosphate sodium and were regarded as the control group. The therapeutic efficacy of the two groups was observed, the improved condition of myocardial enzyme indicator and myocardial troponin I (cTn I) in the two groups were compared before and after the treatment. RESULTS: The total effective rates of the patients in the observation group and the control group were 93.75% and 76.00%, respectively. The clinical efficacy of the observation group was better than that of the control group (p<0.05). The electrocardiogram improvement condition of the observation group was better than that of the control group (p<0.05); after the treatment, the expression levels of lactate dehydrogenase (LDH), aspartate aminotransferase (AST), Creatine Kinase (CK-MB), and cTn I in the observation group were (313.37±9.42) U/L, (29.38±4.97) U/L, (23.67±2.89) U/L, (0.12±0.02) µg/L, respectively. The expression levels of LDH, AST, CK-MB, and cTn I in the control group were (322.43±12.32) U/L, (33.43±5.14) U/L, (26.22±3.37) U/L, (0.24±0.04) µg/L. The levels of myocardial enzyme and cTn I in the observation group and the control group after the treatment were lower than that before the treatment (p<0.05), while the level of myocardial enzyme and cTn I in the observation group after the treatment was significantly lower than that in the control group (p<0.05). CONCLUSIONS: The results indicated that, compared with ribavirin combined with creatine phosphate sodium, ulinastatin combined with creatine phosphate sodium had better clinical efficacy in the treatment of pediatric viral myocarditis. It could significantly improve the level of myocardial enzyme indicator and cTn I, and had certain clinical and promotional values and application values.
Assuntos
Glicoproteínas/uso terapêutico , Miocardite/tratamento farmacológico , Fosfocreatina/uso terapêutico , Ribavirina/uso terapêutico , Viroses/tratamento farmacológico , Adolescente , Criança , Pré-Escolar , Quimioterapia Combinada , Feminino , Glicoproteínas/administração & dosagem , Humanos , Masculino , Miocardite/metabolismo , Fosfocreatina/administração & dosagem , Estudos Retrospectivos , Ribavirina/administração & dosagem , Viroses/metabolismoRESUMO
The present study was designed to further explore the role and the underlying molecular mechanism of phosphocreatine (PCr) for cardiac fibrosis in vivo. Isoproterenol (ISO) was used to induce cardiac fibrosis in rats. PCr administration ameliorated fibrosis by reducing collagen accumulation and fibrosis-related signals, including transforming growth factor beta 1 (TGF-ß1), alpha smooth muscle actin (α-SMA), collagen type I, and collagen type III. Mitogen-activated protein kinases (MAPKs) and nuclear factor kappa B (NF-κB) signaling pathways, including p38, extracellular signal regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p65, were highly activated by ISO and blocked by PCr. Moreover, PCr decreased ISO-induced matrix metalloproteinase-9 (MMP-9) and increased the tissue inhibitor of metalloproteinase-1 (TIMP-1) expression. Furthermore, PCr suppressed cardiomyocyte apoptosis induced by ISO, as shown by downregulated expression of the proapoptotic caspase-3, Bax, and upregulated expression of the antiapoptotic Bcl-2. Taken together, PCr can be an effective agent for preventing cardiac fibrosis and cardiomyocyte apoptosis.
Assuntos
Fibrose/tratamento farmacológico , Cardiopatias/tratamento farmacológico , Miócitos Cardíacos/efeitos dos fármacos , Fosfocreatina/administração & dosagem , Animais , Apoptose/efeitos dos fármacos , Modelos Animais de Doenças , Fibrose/induzido quimicamente , Fibrose/patologia , Regulação da Expressão Gênica/efeitos dos fármacos , Cardiopatias/induzido quimicamente , Cardiopatias/patologia , Humanos , Isoproterenol/toxicidade , Proteínas Quinases JNK Ativadas por Mitógeno/genética , Metaloproteinase 9 da Matriz/genética , Miócitos Cardíacos/metabolismo , Miócitos Cardíacos/patologia , NF-kappa B/genética , Ratos , Transdução de Sinais/efeitos dos fármacos , Inibidor Tecidual de Metaloproteinase-1/genética , Fator de Crescimento Transformador beta1/genéticaRESUMO
BACKGROUND: Major depressive disorder (MDD) is a common psychiatric disorder. With systematic antidepressant treatment, 50-75% of patients have a treatment response but require 4-6 weeks to have their symptoms alleviated. Therefore, researchers anticipate the development of novel fast-acting antidepressants. Previous studies have revealed that the decrease of bio-energetic metabolism may contribute to the occurrence of depression, while our team has found adenosine triphosphate (ATP) and phosphocreatine (PCr) to be fast-acting antidepressants in the depressed-animal model. ATP and PCr have already been widely prescribed clinically as energy supplements for cells. This will be the first clinical attempt of the intravenous administration of ATP and PCr combined with orally administered fluoxetine in MDD. METHODS: This is a single-center, randomized, double-blind, placebo-controlled pilot study. A total of 42 patients will be divided randomly into three groups. Patients will receive an intravenous administration of ATP or PCr or saline twice daily combined with orally administered fluoxetine (20 mg/day) for the first 2 weeks and fluoxetine monotherapy for the following 4 weeks. Follow-up assessment will be completed at week 10. Feasibility outcomes will include percentages of patient eligibility, intention to use medication, willingness to participate, drug adherence, completion of the scheduled assessment, retention, drop-out, etc. Physical examination results, Side Effect Rating Scale, adverse events, results from blood tests, electroencephalogram, and electrocardiograph will be recorded for safety evaluation of the augmentation therapy. The trends of efficacy will be evaluated by the reduction rate of the Hamilton Depression Rating Scale, the mean change of the Clinical Global Impression Scale, and the Patients Health Questionaire-9 items. DISCUSSION: In our study, ATP and PCr will be given by intravenous infusion. Thus patients will be hospitalized for the initial 2 weeks for safety concern. Hospitalization will be an impact factor for the recruitment, participation, drop-out, efficacy, results, etc. The evaluation of our feasibility outcomes, study setting, safety of augmentation therapy and possible efficacy trends among groups, will facilitate a full-scale trial design and sample size calculation. TRIAL REGISTRATION: NCT03138681 . Registered on 3 May 2017. First patient: 4 May 2017.
Assuntos
Trifosfato de Adenosina/administração & dosagem , Afeto/efeitos dos fármacos , Antidepressivos de Segunda Geração/administração & dosagem , Transtorno Depressivo Maior/tratamento farmacológico , Fluoxetina/administração & dosagem , Fosfocreatina/administração & dosagem , Inibidores Seletivos de Recaptação de Serotonina/administração & dosagem , Trifosfato de Adenosina/efeitos adversos , Administração Intravenosa , Administração Oral , Adolescente , Adulto , Idoso , Antidepressivos de Segunda Geração/efeitos adversos , China , Transtorno Depressivo Maior/diagnóstico , Transtorno Depressivo Maior/psicologia , Método Duplo-Cego , Esquema de Medicação , Quimioterapia Combinada , Estudos de Viabilidade , Feminino , Fluoxetina/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Questionário de Saúde do Paciente , Fosfocreatina/efeitos adversos , Projetos Piloto , Ensaios Clínicos Controlados Aleatórios como Assunto , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
OBJECTIVE: There is experimental evidence that phosphocreatine (PCr) can decrease ischemia/reperfusion injury of the heart. The authors investigated if PCr would improve heart performance as compared with standard treatment in cardiac surgery. DESIGN: Meta-analysis of randomized controlled trials. SETTING: Hospitals. PARTICIPANTS: Adult and pediatric patients undergoing cardiac surgery. INTERVENTIONS: The ability of PCr to improve cardiac outcomes as compared with standard treatment was investigated. MEASUREMENTS AND MAIN RESULTS: PubMed/Medline, Embase, Scopus, Cochrane Library, China National Knowledge Infrastructure, WANGFANG DATA, and VIP Paper Check System were searched to March 1 2017. The authors included 26 randomized controlled trials comprising 1,948 patients. Random and fixed-effects models were used to estimate odds ratio (OR) and mean difference (MD) with 95% confidence interval (CI). PCr use was associated with reduced rates of intraoperative inotropic support (27% v 44%; OR 0.47, 95% CI 0.35-0.61; p < 0.001), major arrhythmias (16% v 28%; OR 0.44, 95% CI 0.27-0.69; p < 0.001), as well as increased spontaneous recovery of the cardiac rhythm immediately after aortic declamping (50% v 34%; OR 2.45, 95% CI 1.82-3.30; p < 0.001) as compared with standard treatment. The use of PCr decreased myocardial damage and augmented left ventricular ejection fraction in the postoperative period; however, MD for these outcomes were small and do not seem to be clinically significant. CONCLUSIONS: In randomized trials, PCr administration was associated with reduced rates of intraoperative inotropic support and major arrhythmias, and increased spontaneous recovery of the cardiac rhythm after aortic declamping. Large multicenter evidence is needed to validate these findings.
Assuntos
Procedimentos Cirúrgicos Cardíacos/métodos , Cardiotônicos/administração & dosagem , Fosfocreatina/administração & dosagem , Complicações Pós-Operatórias/prevenção & controle , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Administração Intravenosa , Procedimentos Cirúrgicos Cardíacos/efeitos adversos , Humanos , Complicações Pós-Operatórias/epidemiologiaRESUMO
BACKGROUND: Creatine phosphate (CrP) plays a fundamental physiological role by providing chemical energy for cell viability and activity, especially in muscle tissue. Numerous pathological conditions, caused by acute or chronic ischaemic situations, are related to its deficiency. For these reasons, it has been used as a cardioprotective agent in heart surgery and medical cardiology for many years. OBJECTIVE: This article gives a brief overview of the main characteristics of exogenous CrP. METHODS: Previous review articles on CrP were screened for relevant information and references. Results from selected studies were reviewed and classified according to the topics in this review article and provided further interesting information on the pharmacological role of this molecule. RESULTS: Besides CrP's well known cell energy and function restoring properties, new evidence is emerging regarding its antioxidant and anti-apoptotic properties. Use of CrP is well established clinically as an intraoperative and perioperative adjuvant in heart operations (valve replacement, coronary artery bypass grafting, congenital heart defect repair), and as an additional agent in medical cardiology therapy for acute myocardial infarction and acute and chronic heart failure. In particular, there are promising potential new CrP uses in neurology, such as in cerebral ischaemia and hypoxic ischaemic encephalopathy. CONCLUSIONS: This review article describes the role of CrP treatment in cardiological indications, such as cardioprotection in cardioplegia and in myocardiopathies of various etiopathogenesis, as well as in other clinical indications such as skeletal muscle rehabilitation and neurological conditions.
Assuntos
Pesquisa Biomédica/tendências , Cardiologia , Metabolismo Energético/efeitos dos fármacos , Cardiopatias/tratamento farmacológico , Miocárdio/metabolismo , Fosfocreatina/administração & dosagem , Cardiotônicos/administração & dosagem , Cardiopatias/metabolismo , HumanosRESUMO
OBJECTIVE: To evaluate the effect of exogenous creatine phosphate (CP) on myocardial injury after percutaneous coronary intervention (PCI). METHOD: Four hundred patients were divided to receive conventional therapy (control group) or 3-day intravenous infusion of CP after PCI (CP group). Levels of creatine kinase MB (CK-MB) and troponin I (TnI) were measured before and on postprocedural day 3. RESULTS: Postprocedural CK-MB and TnI in the CP group were significantly increased compared to the control group. In the CP group, 8.0% and 5.0% of patients had an increase in CK-MB 1 to 3 times and >3 times, respectively, which were significantly lower than that of the control group (19.0% and 9.0%, respectively); 12.0% and 10.0% of patients had an increase in TnI 1 to 3 times and >3 times, respectively, which were significantly lower than that of the control group (21.0% and 18.0%, respectively). CONCLUSION: Exogenous CP was helpful to reduce myocardial injury after PCI.
Assuntos
Traumatismo por Reperfusão Miocárdica/prevenção & controle , Intervenção Coronária Percutânea/efeitos adversos , Fosfocreatina/administração & dosagem , Idoso , Biomarcadores/sangue , China , Creatina Quinase Forma MB/sangue , Citoproteção , Esquema de Medicação , Feminino , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Traumatismo por Reperfusão Miocárdica/sangue , Traumatismo por Reperfusão Miocárdica/diagnóstico , Traumatismo por Reperfusão Miocárdica/etiologia , Fatores de Tempo , Resultado do Tratamento , Troponina I/sangue , Regulação para CimaRESUMO
The functional activity of mitochondria of the muscular coat of small intestine (MCSI) has been studied in the normal state and under experimental widespread purulent peritonitis (WPP) conditions. The experiments have been carried out on a group of 55 male rabbits of chinchilla breed. It is established that, as a result of the WPP development, the functional activity of mitochondria in MCSI considerably decreases. The comparative analysis of the efficiency of metabolic drugs cytoflavin and neoton showed advantage of the citoflavin preparation, the administration of which allowed the indices of mitochondria in intact animals to be exceeded on the fifth day of postoperative period. The research results show expediency of a complex treatment of WPP using cytoflavin preparation for the normalization of biological oxidation processes and elimination of enteric insufficiency.
Assuntos
Mononucleotídeo de Flavina/uso terapêutico , Inosina Difosfato/uso terapêutico , Intestino Delgado/efeitos dos fármacos , Mitocôndrias/efeitos dos fármacos , Niacinamida/uso terapêutico , Fosforilação Oxidativa/efeitos dos fármacos , Peritonite/tratamento farmacológico , Fosfocreatina/uso terapêutico , Succinatos/uso terapêutico , Animais , Bacillus , Combinação de Medicamentos , Escherichia coli , Mononucleotídeo de Flavina/administração & dosagem , Injeções Intraperitoneais , Injeções Intravenosas , Inosina Difosfato/administração & dosagem , Intestino Delgado/metabolismo , Intestino Delgado/patologia , Masculino , Mitocôndrias/metabolismo , Músculo Liso/efeitos dos fármacos , Músculo Liso/metabolismo , Músculo Liso/patologia , Niacinamida/administração & dosagem , Peritonite/metabolismo , Peritonite/patologia , Fosfocreatina/administração & dosagem , Coelhos , Succinatos/administração & dosagem , SupuraçãoRESUMO
Experiments on 55 male chinchilla rabbits with model widespread purulent peritonitis have been performed for determinig structural changes in adrenal glands with the aid of optical microscopy. The introduction of aerobic-anaerobic culture of E. Coli and B. Fragilis into the abdominal cavity causes expressed structural changes in parenchyma of adrenal glands within 6 hours. It is established for the first time that the administration of metabolic drugs citoflavin (containing succinic acid) and neoton (containing creatine phosphate) prevents the development of pathological structural changes in adrenal glands under conditions of experimental widespread purulent peritonitis.
Assuntos
Glândulas Suprarrenais/efeitos dos fármacos , Infecções por Bacteroides/tratamento farmacológico , Infecções por Escherichia coli/tratamento farmacológico , Peritonite/tratamento farmacológico , Fosfocreatina/uso terapêutico , Ácido Succínico/uso terapêutico , Glândulas Suprarrenais/metabolismo , Glândulas Suprarrenais/microbiologia , Glândulas Suprarrenais/patologia , Animais , Infecções por Bacteroides/metabolismo , Infecções por Bacteroides/microbiologia , Bacteroides fragilis/efeitos dos fármacos , Bacteroides fragilis/crescimento & desenvolvimento , Escherichia coli/efeitos dos fármacos , Escherichia coli/crescimento & desenvolvimento , Infecções por Escherichia coli/metabolismo , Infecções por Escherichia coli/microbiologia , Injeções Intravenosas , Masculino , Microscopia , Microtomia , Inclusão em Parafina , Peritonite/metabolismo , Peritonite/microbiologia , Fosfocreatina/administração & dosagem , Coelhos , Ácido Succínico/administração & dosagem , SupuraçãoRESUMO
The research was performed in 55 male chinchilla rabbits. For the first time the effect of metabolic preparations "citoflavin" and "neoton" of the protein-lipid spectrum of blood was studied in experimental diffuse purulent peritonitis. The development of diffuse purulent peritonitis caused negative changes in blood lipid-transport system which resulted in a decreased blood protein level and high density lipoproteins (HDL) and growth of triglycerides. In the HDL phospholipid spectrum the pathological changes are characterized by an increased lisophosphotide content and compensatory growth of the level of poliglycerophosphatides. A comparative analysis has shown that both preparations possess unidirectional action which is more pronounced in "citoflavin" than in "neoton".
Assuntos
Mononucleotídeo de Flavina , Inosina Difosfato , Laparotomia , Metabolismo dos Lipídeos/efeitos dos fármacos , Niacinamida , Lavagem Peritoneal , Peritonite , Fosfocreatina , Succinatos , Animais , Transporte Biológico/efeitos dos fármacos , Terapia Combinada , Combinação de Medicamentos , Monitoramento de Medicamentos/métodos , Mononucleotídeo de Flavina/administração & dosagem , Mononucleotídeo de Flavina/farmacocinética , Infusões Intravenosas/métodos , Inosina Difosfato/administração & dosagem , Inosina Difosfato/farmacocinética , Masculino , Modelos Animais , Niacinamida/administração & dosagem , Niacinamida/farmacocinética , Peritonite/metabolismo , Peritonite/fisiopatologia , Peritonite/terapia , Fosfocreatina/administração & dosagem , Fosfocreatina/farmacocinética , Substâncias Protetoras/administração & dosagem , Substâncias Protetoras/farmacocinética , Coelhos , Relatório de Pesquisa , Succinatos/administração & dosagem , Succinatos/farmacocinética , Supuração/metabolismo , Supuração/terapia , Fatores de Tempo , Resultado do Tratamento , Vitaminas/administração & dosagem , Vitaminas/farmacocinéticaRESUMO
Structural changes in the heart are studied at an experimental widespread purulent peritonitis. It was established that in 6 hours after initiation of peritonitis in a myocardium the severe disorders of blood circulation, interstitial edema, the phenomena of kariopyknosis, development of systemic toxic damages specifying in high speed at this disease were observed. One of the mechanism of their development is a energy deficiency. The proof of this is destructive changes of cardiomyocytes mitochondria. The comparative analysis of use of metabolic preparations "Citoflavin", containing amber acid, and "Neoton", containing phosphocreatine, for the purpose of pharmacological support of cardiac activity at an experimental widespread purulent peritonitis has revealed high efficiency of the preparation "Citoflavin". It caused more intensive decrease of inflammatory changes in a myocardium, preventing of cardiomyocytes necrobiosis, contribution to preservation of normal structure and growth of quantity of mitochondria.
Assuntos
Cardiopatias , Mitocôndrias Cardíacas/metabolismo , Miocárdio/metabolismo , Fosfocreatina/administração & dosagem , Animais , Cardiotônicos/administração & dosagem , Modelos Animais de Doenças , Cardiopatias/etiologia , Cardiopatias/metabolismo , Cardiopatias/patologia , Cardiopatias/prevenção & controle , Mitocôndrias Cardíacas/patologia , Miocárdio/patologia , Órgãos em Risco , Peritonite/induzido quimicamente , Peritonite/complicações , Peritonite/metabolismo , Fotomicrografia/métodos , Coelhos , Índice de Gravidade de Doença , Supuração/etiologia , Supuração/metabolismo , Resultado do TratamentoRESUMO
Were analyzed publications devoted to the problem of diagnostics and treatment of posthypoxia myocardial ischemia. A description and estimation of the pathophysiological processes occurring in children who had perinatal hypoxia. The analysis of changes in the myocardium, and violations of intracardiac hemodynamics in newborns with posthypoxia myocardial ischemia. Describes modern methods of treatment of myocardial ischemia, including use of phosphokreatinine as a cardiotrophic therapy.
Assuntos
Hipóxia/complicações , Doenças do Recém-Nascido/terapia , Isquemia Miocárdica/terapia , Ecocardiografia/métodos , Hemodinâmica , Humanos , Recém-Nascido , Doenças do Recém-Nascido/diagnóstico , Doenças do Recém-Nascido/fisiopatologia , Isquemia Miocárdica/diagnóstico , Isquemia Miocárdica/fisiopatologia , Miocárdio/patologia , Fosfocreatina/administração & dosagem , Fosfocreatina/análogos & derivados , Fosfocreatina/uso terapêutico , Índice de Gravidade de DoençaRESUMO
The effect of citoflavin and neoton preparations on the migration activity of neutrophil granulocytes under action of mitogen-induced immunocompetent blood cells, Peyer's patches, spleen and inguinal lymph was studied on a group of 55 male chinchilla rabbits with experimental model of widespread purulent peritonitis. It is established that the regulating action of immunocompetent cells on the migration of neutrophil leukocytes under the conditions of widespread purulent peritonitis is stable and widespread process, which is observed within 5 days of the postoperative period. The use of citoflavin and neoton during the postoperative period produces correction of the activity of immunocompetent cells, changing their properties in regulation of the migratory activity of neutrophil granulocytes. The effect is characteristic of both preparations and it is observed in all investigated organs, being manifested to a greater degree in immunocompetent cells of peripheral blood and Peyer's patches. Metabolic preparation citoflavin exhibits a more pronounced immunotropic action in comparison to neoton, which contains creatine phosphate.
Assuntos
Movimento Celular/efeitos dos fármacos , Mononucleotídeo de Flavina/administração & dosagem , Inosina Difosfato/administração & dosagem , Niacinamida/administração & dosagem , Peritonite/tratamento farmacológico , Peritonite/imunologia , Nódulos Linfáticos Agregados/efeitos dos fármacos , Baço/imunologia , Succinatos/administração & dosagem , Animais , Cardiotônicos/administração & dosagem , Cardiotônicos/uso terapêutico , Movimento Celular/imunologia , Modelos Animais de Doenças , Combinação de Medicamentos , Escherichia coli/imunologia , Mononucleotídeo de Flavina/uso terapêutico , Virilha , Humanos , Inosina Difosfato/uso terapêutico , Linfonodos/citologia , Linfonodos/efeitos dos fármacos , Linfonodos/imunologia , Linfócitos/efeitos dos fármacos , Linfócitos/imunologia , Masculino , Monócitos/efeitos dos fármacos , Monócitos/imunologia , Fármacos Neuroprotetores/administração & dosagem , Fármacos Neuroprotetores/uso terapêutico , Neutrófilos/efeitos dos fármacos , Neutrófilos/imunologia , Niacinamida/uso terapêutico , Peritonite/microbiologia , Nódulos Linfáticos Agregados/imunologia , Fosfocreatina/administração & dosagem , Fosfocreatina/uso terapêutico , Período Pós-Operatório , Coelhos , Baço/citologia , Baço/efeitos dos fármacos , Succinatos/uso terapêutico , SupuraçãoRESUMO
The influence of creatine or its derivates on the cell energy potential may be one of the possibl approaches to induce neuroprotection. Effect of creamide (creatinylglycine ethylic ether fumarate) on the brain injury was studied in the experimental model of the brain ischemia/reperfusion in rats. The experiments were carried out in 14-20 weeks old male Wistar rats weighing 240-300 g, anesthetized by chloral hydrate (430 mg/kg). Creamide was administered intravenously at the doses of 50, 70, 140, and 280 mg/kg. For comparison phosphocreatine was used at the dose of 255 mg/kg. Creamide and phosphocreatine were administered intravenously (in volume of 1 ml within 5 min) 30 min before cerebral middle artery occlusion. Focal cerebral ischemia for 30 min was produced by endovascular suture occlusion with the subsequent 48 h reperfusion period. Creamide administration resulted in dose-dependent decrease of brain ischemic injury. Creamide administered at the doses of 140 and 280 mg/kg was more effective as compared with phosphocreatine (255 mg/kg). The data obtained open new perspectives for further research and development of new creatine-derived drugs with neuroprotective action.
Assuntos
Isquemia Encefálica/tratamento farmacológico , Encéfalo/efeitos dos fármacos , Infarto da Artéria Cerebral Média/tratamento farmacológico , Fármacos Neuroprotetores/uso terapêutico , Fosfocreatina/análogos & derivados , Fosfocreatina/uso terapêutico , Traumatismo por Reperfusão/tratamento farmacológico , Animais , Encéfalo/fisiopatologia , Isquemia Encefálica/fisiopatologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Infarto da Artéria Cerebral Média/fisiopatologia , Injeções Intravenosas , Masculino , Fármacos Neuroprotetores/administração & dosagem , Fosfocreatina/administração & dosagem , Ratos , Ratos Wistar , Traumatismo por Reperfusão/fisiopatologia , Fatores de TempoRESUMO
This article is report the study of the pharmacokinetics and metabolic disposition of exogenous phosphocreatine (PCr) in rats by means of an ion-pair HPLC-UV assay. PCr and its metabolite creatine (Cr) and related-ATP in rat plasma and red blood cell (RBC) were simultaneously determined. A blank plasma and RBC were initially run for baseline subtraction. Plasma and RBC samples were deproteinized with 6% PCA prior to HPLC. Following i.v. administration of PCr 500 mg x kg(-1) and 1 000 mg x kg(-1) the C-T curve could be described by the two-compartment model with t1/2beta 22.5-23.3 min, V(d) 0.956 4-0.978 6 L x kg(-1), CL 0.029 L. kg(-1) x min(-1). The Cr as PCr degraded product appeared as early as 2 min post i.v. dosing with t(max) 20 min, t1/2kappa (m) 40.6-42.7 min and f(m) 60%-76%. After po administration of PCr, the parent drug in plasma was undetectable, but the metabolite Cr was detected with t(max) 65-95 min, t1/2kappa (m) 56.0-57.7 min, metabolite-based bioavailability F(m) 55.02%-62.31%. PCr i.v. administration resulted in significant elevation of ATP level in RBC but not in plasma, the related-ATP in RBC was characterized by t(max) 68-83 min, t1/2kappa 49-52 min. In RBC no exogenous PCr was found but Cr was detected following i.v. administration of PCr, with the t(max) 120 min and t1/2k (m) 70 min for Cr. The above results indicate that PCr eliminates and bio-transforms in body very rapidly; K > K(m) confers ERL, instead of FRL, type upon the metabolic disposition of Cr. Following po administration of PCr, the degraded product Cr is absorbed but not the parent drug PCr. The formed Cr can be accounted for by most of i.v. and po PCr. Intravenous dosing leads apparently increased and sustained Cr and related-ATP concentration in RBC.
Assuntos
Cardiotônicos/farmacocinética , Creatina/farmacocinética , Fosfocreatina/farmacocinética , Trifosfato de Adenosina/sangue , Trifosfato de Adenosina/farmacocinética , Administração Oral , Animais , Área Sob a Curva , Disponibilidade Biológica , Biotransformação , Cardiotônicos/administração & dosagem , Cardiotônicos/sangue , Creatina/administração & dosagem , Creatina/metabolismo , Eritrócitos/metabolismo , Injeções Intravenosas , Masculino , Fosfocreatina/administração & dosagem , Fosfocreatina/sangue , Ratos , Ratos Sprague-DawleyRESUMO
The purpose of this study was to determine the effect of 30 days of single-dose creatine supplementation with phosphate salts (CPS) on body weight (BW) and anaerobic working capacity (AWC) in men. Using a double-blind design, 32 men randomly received 1 serving of either CPS (5 g Cr + 4 g phosphate) (n = 17) or 20 g of dextrose as placebo (PL) (n = 15) for 30 days. AWC determined from the Critical Power Test and BW were measured at baseline, 10 days, 20 days, 30 days, and 10 days post-supplementation. Results (2 x 5 ANOVA) showed no significant differences between groups for AWC at any time point; however, BW was significantly increased at 10 days in the CPS group (1.0 kg) vs. PL (0.0 kg), and remained elevated for the duration of the study. These findings suggest that a single 5 g x d(-1) dose of CPS for 30 days increases BW but is not effective for increasing AWC in men.
Assuntos
Peso Corporal/efeitos dos fármacos , Músculo Esquelético/efeitos dos fármacos , Fosfocreatina/administração & dosagem , Resistência Física/efeitos dos fármacos , Adulto , Limiar Anaeróbio/efeitos dos fármacos , Análise de Variância , Suplementos Nutricionais , Método Duplo-Cego , Esquema de Medicação , Humanos , Masculino , Músculo Esquelético/fisiologia , Educação Física e Treinamento/métodos , Probabilidade , Valores de Referência , Sensibilidade e EspecificidadeRESUMO
BACKGROUND/PURPOSE: The skin has the unique ability to survive ischemia associated with skin grafts, flaps and hair transplantation procedures. Spectroscopic data later confirmed by chromatography, immunohistochemistry and molecular biology techniques identified the presence of large quantities of phosphocreatine in human skin. Phosphocreatine molecules regenerate ATP cellular reserves during ischemia. This reaction is mediated by creatine phosphokinase enzymes that were also isolated and studied in normal and diseased skin. METHODS: Literature search revealed important contributions by US, Swiss, German, French, Scandinavian and Japanese investigators in the development and understanding of this research field. RESULTS: Serum creatine phosphokinase levels are elevated in burn victims and patients with toxic epidermal necrolysis. Phosphocreatine concentration and creatine phosphokinase activity are elevated in psoriatic skin and in non-melanoma malignancies in comparison with normal skin. Furthermore, skin phosphocreatine and creatine phosphokinase enzymes are localized almost exclusively within the epidermis and in hair follicles. Finally, phosphocreatine and creatine phosphokinase enzymes help to protect skin from UV damage. CONCLUSIONS: Clearly, this research area is only starting to be appreciated by the scientific community. Topical and systemic phosphocreatine administration appears to reverse photodamage and improve wound healing. Spectroscopic monitoring of phosphocreatine and related phosphometabolites can be potentially used to monitor disease activity and respond to therapy in psoriasis, leg ulcers, skin malignancies and other skin conditions.
Assuntos
Creatina Quinase/metabolismo , Fosfocreatina/administração & dosagem , Fosfocreatina/metabolismo , Dermatopatias/tratamento farmacológico , Dermatopatias/metabolismo , Pele/efeitos dos fármacos , Pele/metabolismo , Biomarcadores/análise , Humanos , Dermatopatias/diagnósticoRESUMO
AIM: Off pump coronary artery bypass grafting (OPCAB) involves, and is occasionally impaired by obligatory regional myocardial ischemia, particularly with the use of proximal coronary in-flow occlusion techniques. Intracoronary shunts do not guarantee absence of distal ischemia given their small inner diameter and the presence of proximal coronary stenosis. Additional adjunctive measures to provide short-term myocardial protection may facilitate OPCAB. High-energy phosphate supplementation with creatine phosphate prior to ischemia may attenuate ischemic dysfunction. METHODS: In a rodent model of a transient coronary occlusion and myocardial ischemia, 36 animals underwent preischemic intravenous infusion of either creatine phosphate or saline, 10 minutes of proximal left anterior descending (LAD) occlusion, and 10 minutes of reperfusion. Rats underwent continuous intracavitary pressure monitoring and cellular ATP levels were quantified using a luciferin/luciferase bioluminescence assay. RESULTS: Within 2 minutes of ischemia onset, creatine phosphate animals exhibited statistically significant greater preservation of myocardial function compared to controls, an augmentation which persisted throughout the duration of ischemia and subsequent reperfusion. Furthermore, significantly greater cellular ATP levels were observed among creatine phosphate treated animals (344+/-55 nMol/g tissue, n=5) compared to control animals (160+/-9 nMol/g tissue, n=5)(p=0.014). CONCLUSIONS: A strategy of intravenous high-energy phosphate administration successfully prevented ischemic ventricular dysfunction in a rodent model of OPCAB.
Assuntos
Cardiotônicos/administração & dosagem , Ponte de Artéria Coronária sem Circulação Extracorpórea/métodos , Isquemia Miocárdica/prevenção & controle , Fosfocreatina/administração & dosagem , Trifosfato de Adenosina/metabolismo , Animais , Modelos Animais de Doenças , Infusões Intravenosas , Masculino , Isquemia Miocárdica/metabolismo , Isquemia Miocárdica/fisiopatologia , Miocárdio/metabolismo , Ratos , Ratos Wistar , Volume Sistólico/efeitos dos fármacos , Volume Sistólico/fisiologia , Resultado do Tratamento , Troponina I/sangueRESUMO
BACKGROUND: The aim of this study was to characterize the muscular reservoirs of phosphorilated energetic components of athletes using 31P-MRS. METHODS: The sample was formed by 14 elite athletes from the Center for High Sportive Performance (CAR, Sant Cugat del Vallés, Spain). The pattern of the phosphorilated metabolites was measured from the muscle vastus medialis by 31P-MRS. Oral supplementation of 20 g of Creatine monohydrate was given during 14 days. Two groups of athletes were formed according to their physical characteristics (weight, height, body mass index, maximum O2 uptake). The first group received a placebo (maltodextrine), while the second group received a diet of creatine supplement. The exercise was performed inside the resonance tunnel with a frequency of 60 RPM with both legs. RESULTS: The results showed that significant decrease occurred in phosphocreatine (PCr), inorganic phosphate (Pi) and intracellular pH after supplementation. CONCLUSION: It was concluded that the exercise performed by the long distance runners recruited in this study, detected by 31P-MRS, reduced the consumption of PCr during exercise owing to creatine supplementation diet.
Assuntos
Metabolismo Energético/fisiologia , Exercício Físico/fisiologia , Espectroscopia de Ressonância Magnética , Músculo Esquelético/metabolismo , Fosfocreatina/metabolismo , Esportes/fisiologia , Adulto , Índice de Massa Corporal , Protocolos Clínicos , Suplementos Nutricionais , Humanos , Fosfocreatina/administração & dosagemRESUMO
Creatine is a popular supplement used by athletes in an effort to increase muscle performance. The purpose of this review was to assess the literature evaluating the effects of creatine supplementation on renal function. A PubMed search was conducted to identify relevant articles using the keywords, creatine, supplementation, supplements, renal dysfunction, ergogenic aid and renal function. Twelve pertinent articles and case reports were identified. According to the existing literature, creatine supplementation appears safe when used by healthy adults at the recommended loading (20 gm/day for five days) and maintenance doses (=3 gm/day). In people with a history of renal disease or those taking nephrotoxic medications, creatine may be associated with an increased risk of renal dysfunction. One case report of acute renal failure was reported in a 20-year-old man taking 20 gm/day of creatine for a period of four weeks. There are few trials investigating the long-term use of creatine supplementation in doses exceeding 10 gm/day. Furthermore, the safety of creatine in children and adolescents has not been established. Since creatine supplementation may increase creatinine levels, it may act as a false indicator of renal dysfunction. Future studies should include renal function markers other than serum creatinine and creatinine clearance.